Exhibit 12.1
ZIOPHARM Oncology, Inc.
Computation of Ratio of Earnings to Fixed Charges
and to Combined Fixed Changes and Preference Dividends
| Year Ended December 31, | Nine Months Ended September 30, | |||||||||||||||||||||||
$ In Thousands, Except Ratio | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | ||||||||||||||||||
Fixed charges: | ||||||||||||||||||||||||
Interest Expense | $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | ||||||||||||
Amortized premiums discounts and capitalized expenses related to indebtedness | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | — | $ | — | $ | — | $ | — | $ | — | $ | — | |||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Earnings (loss): | ||||||||||||||||||||||||
Net income (loss) before tax benefit (provision) | $ | (7,649 | ) | $ | (32,670 | ) | $ | (63,778 | ) | $ | (96,132 | ) | $ | (57,107 | ) | $ | (21,380 | ) | ||||||
Add fixed charges | — | — | — | — | — | — | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| $ | (7,649 | ) | $ | (32,670 | ) | $ | (63,778 | ) | $ | (96,132 | ) | $ | (57,107 | ) | $ | (21,380 | ) | |||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Ratio of earnings to fixed charges | * | * | * | * | * | * | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
Deficiency of earnings to fixed charges | $ | (7,649 | ) | $ | (32,670 | ) | $ | (63,778 | ) | $ | (96,132 | ) | $ | (57,107 | ) | $ | (21,380 | ) | ||||||
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||
| * | Less than one to one coverage |
